Bridgepoint $BPT is preparing a potential sale of Danish counter-drone company MyDefence at roughly $1B, the FT reported on June 14. The report says an adviser has been hired for a possible year-end auction and that MyDefence sales are poised to more than double this year.
The SEC proposed rescinding Regulation NMS Rules 611 and 610(e), removing the trade-through prohibition and locked/crossed-quote restrictions for NMS stocks, with comments due 60 days after Federal Register publication.
$SPCX closed at $160.95, up more than 19% from its $135 IPO price, putting SpaceX near a $2.1T market value after more than 500M shares traded in its first Nasdaq session.
Chow Tai Fook (1929.HK) rose 15% after FY2026 profit attributable to shareholders increased 52.2% to HK$9.004B. The company reported revenue of HK$94.398B, gross margin of 32.3% and operating profit margin of 20.0%.
Oracle $ORCL fell as much as 11% after Q4 results, with CNBC citing investor concern over a FY2027 funding plan of about $40B. Oracle’s release showed FY2026 free cash flow at negative $23.7B, RPO of $638B and Q4 non-GAAP EPS of $2.11.
SpaceX priced 555,555,555 Class A shares at $135, raising about $75B before a June 12 Nasdaq debut under $SPCX. The company also granted underwriters a 30-day option for 83,333,333 additional shares, making the offering a benchmark event for IPO and index investors.
Hugo Boss shares rose 8% after Frasers Group launched a $2B takeover offer, according to CNBC. Frasers already owns roughly 26% of the German fashion group, making the bid a material European retail M&A event.
Super Micro Computer $SMCI fell 9% in extended trading after proposing $7.0B of equity and equity-linked financing. The company tied the capital raise to about $39B of recent AI-server orders from more than 20 customers.
GSK $GSK agreed to acquire Nuvalent $NUVL for $10.6B in cash, offering $124 a share and a 40% premium to Nuvalent’s prior close. The transaction gives GSK two late-stage lung-cancer assets under U.S. FDA review for 2026 approvals.
Zealand Pharma $ZLDPF fell more than 24% after full Phase III survodutide data showed GI-event discontinuations of 19% versus 2.9% on placebo. The same program showed up to 16.6% weight loss, 34% visceral-fat reduction, and 63.1% liver-fat reduction.
Marvell Technology $MRVL traded up 8.8% premarket after S&P Dow Jones Indices said it will enter the S&P 500 before the June 22 open. The index change adds a passive-flow catalyst to a chip stock already up 210% year to date, according to CNBC market data.
Lululemon $LULU traded down 8.6% after fiscal Q1 revenue rose 4% to $2.47B but FY2026 EPS guidance was cut to $10.95-$11.15. Americas comparable sales fell 5%, while gross margin compressed 410 bps to 54.2%.